Base Pair Biotechnologies, “The Aptamer Discovery Company™” has been recently awarded a grant from NIH entitled, “Aptamer engineering of lentiviral vectors for cardiac gene therapies”.

HOUSTON, Sept. 27, 2023 /PRNewswire-PRWeb/ — Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden death in young individuals. HCM is also the most prevalent genetic cardiomyopathy affecting Americans (1/200 adults) with no current treatments. Gene therapy approaches that drive the overexpression of the correct genes can be used to remodel the heart tissue and restore function. However, no gene therapies have been developed for in vivo targeting of the heart to date. A key bottleneck in the field is the (in)ability to engineer advanced viral vectors with prescribed tropism in the patient’s body.

Aptamers are short, single-stranded snippets of DNA or RNA that have been selected to bind other molecules in lieu of antibodies. Aptamers have been utilized in many assay formats and as therapeutics, but there is no commercial example of an aptamer being utilized as a delivery vehicle.

In partnership with a cutting-edge start-up that currently remains in “stealth mode”, Base Pair will discover and deploy novel aptamers to help guide viral vectors specifically to the heart.

Upon notice of the grant award from NIH, Dr. Bill Jackson, CEO of Base Pair said, “This is a remarkable opportunity for aptamer technology that very few have even considered. Partnering with experts that understand the challenges associated with delivering gene therapies, specifically to cardiac tissues represents a powerful pairing of technologies.”

For more information or for investor information, please direct all inquiries to [email protected]

About Base Pair:

Founded in 2012, Base Pair Biotechnologies, Inc. is the leading and most experienced custom aptamer development company. Our team of scientists has a combined 50+ person-years of experience in developing aptamers for various targets. In addition to this expertise, Base Pair owns the sole worldwide rights to patents for multiplexed aptamer discovery. More specifically, we have the capability to select aptamers to up to 1000’s of protein, peptide, or small molecule targets in true competitive, multiplexed fashion. The resulting aptamers are therefore more specific for their particular targets. Using this technology, we have completed contracts from the National Cancer Institute, for example, to generate aptamers to 75 cancer biomarker proteins. We routinely work with the largest pharma and biotechnology companies in the world on novel aptamer discovery projects as well as with numerous renowned universities and research institutions to deliver rapid solutions to complex problems.

Media Contact

Bill Jackson, Ph.D., Base Pair Biotechnologies, 1 832305518, [email protected], www.basepairbio.com

SOURCE Base Pair Biotechnologies

California State Assemblymember Reggie Jones-Sawyer from the 57th‥Assembly District and Patricia Anton, President of Anton Consulting will be honored September 28 at Vibiana in Downtown Los Angeles.

LOS ANGELES, Sept. 27, 2023 /PRNewswire-PRWeb/ — The L.A. Trust is proud to honor California State Assemblymember Reggie Jones-Sawyer from the 57th‥Assembly District with the Champion Award, and President of Anton Consulting, Patricia Anton with the Visionary Award at The L.A. Trust’s third annual Salute to Student Health. The awards dinner is scheduled for September 28 from 5:30 p.m. to 9:00 p.m. at Vibiana located at 214 S. Main Street in Downtown Los Angeles.

“We are thrilled to recognize these two exceptional leaders for their steadfast dedication to the health and well-being of our youth,” said Maryjane Puffer, Executive Director of The L.A. Trust. “Their work serves as a powerful inspiration for our mission to enhance education and broaden student access to top-tier healthcare in underserved communities throughout Los Angeles.”

The L.A. Trust’s Visionary Award recognizes Assemblymember Jones-Sawyer’s commitment and leadership in crafting forward-thinking policies that promote greater access to healthcare, education, public safety, and enhancing our justice system. The L.A. Trust enthusiastically supports his work on AB 912—The Strategic Anti-Violence Funding Efforts (SAFE) Act. The SAFE Act would help bring essential health services to more young people.

Patricia Anton in collaboration with The L.A. Trust has spearheaded the creation of the groundbreaking Data xChange—a unique database that stands unrivaled on the national stage of school-based health and software giants. The collaboration between The L.A. Trust and Anton Consulting has yielded a HIPAA-compliant solution to anonymously link highly sensitive health records with academic records, such as grades, attendance, and graduation data. This groundbreaking approach ensures that individuals’ health and academic records remain protected and cannot be re-identified. The creation of the Data xChange enables the collective measurement of the impact of school-based health centers on students’ academic success and well-being, and propels the field of public health research forward.

The awards dinner will feature entertainment, a hosted bar, a live auction, and dinner from Micheline-recommended Redbird chef Neal Fraser. Live auction preview and tickets to the event are available online now (https://secure.qgiv.com/event/latrustsalutetostudenthealth/items/)

About The L.A. Trust

The Los Angeles Trust for Children’s Health (The L.A. Trust) is an independent nonprofit agency bridging health and education to achieve student wellness. The L.A. Trust focuses on student health issues, including expanding healthcare access, mental health, substance use prevention, oral health, sexual and reproductive health, data insights, student engagement, and policy and advocacy.

Media Contact

Mariam Jimenez, The Los Angeles Trust for Children’s Health, 1 323-440-3048, [email protected], thelatrust.org 

SOURCE The Los Angeles Trust for Children’s Health

The Leukemia Research Foundation, a nonprofit headquartered in Northfield, IL, has earned the highest possible rating of four stars from Charity Navigator, America’s largest independent charity evaluator. This is the fifth time the Leukemia Research Foundation has earned this top distinction in the last eight years, and the first time it received the rare, perfect score of 100%.

NORTHFIELD, ill., Sept. 27, 2023 /PRNewswire-PRWeb/ — Leukemia Research Foundation Earns Highest Distinction from Charity Navigator

Northfield, IL (September 25, 2023) – The Leukemia Research Foundation, a nonprofit headquartered in Northfield, IL, has earned the highest possible rating of four stars from Charity Navigator, America’s largest independent charity evaluator. This is the fifth time the Leukemia Research Foundation has earned this top distinction in the last eight years, and the first time it received the rare, perfect score of 100%.

Charity Navigator only awards four stars to the most exceptional organizations, evaluating them based on metrics of financial health, accountability, and transparency. The purpose of the rating is to show donors how efficiently a charity will use their support, how well it has sustained its programs and services over time, and its level of commitment to accountability and transparency.

This rating designates the Leukemia Research Foundation as an official “Give with Confidence” charity, recognizing strong financial health and ongoing accountability and transparency.

“We are delighted to provide the Leukemia Research Foundation with third-party accreditation that validates their operational excellence,” said Michael Thatcher, President and CEO of Charity Navigator. “The four-star rating is the highest possible rating an organization can achieve. We are eager to see the good work that the Leukemia Research Foundation is able to accomplish in the years ahead.”

“This prestigious four-star Charity Navigator designation is further validation that our supporters can trust our commitment to good governance and financial health,” said Kevin Radelet, Executive Director. “We are committed to transparency in the work we do in supporting patients and families, and in funding leukemia research that breaks new ground in the diagnosis and treatment of all types of leukemia.”

Detailed information about the Leukemia Research Foundation’s rating can be found on Charity Navigator’s website. To learn more about the Leukemia Research Foundation or to donate, visit their website at leukemiarf.org.

Media Contact

Maureen Jones, Leukemia Research Foundation, 1 847.919.6250, [email protected], leukemiarf.org

SOURCE Leukemia Research Foundation